Tillomed Laboratories Limited, a European arm of Emcure Pharmaceuticals Ltd, has signed an Asset Purchase Agreement (APA) with UK-based Manx Healthcare Limited and its subsidiaries, Manx Pharma Ltd and Manx Generics Ltd.
The strategic acquisition includes Manx’s entire product portfolio, comprising Marketing Authorisations, Dossiers, Intellectual Property, and inventory. The deal is valued at approximately £19.7 million, including £4.7 million for inventory. Tillomed will pay £6.2 million upfront, with the remainder structured as milestone payments over the next 18 months.
This move marks a significant step in Tillomed’s European growth strategy. By acquiring Manx’s established and quality-driven portfolio, Tillomed aims to expand its therapeutic offerings and strengthen its position in the UK and wider European pharmaceutical markets.
Ajit Srimal, CEO of Tillomed, stated, “Through the acquisition of Manx’s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.”
The acquisition aligns with Emcure’s broader mission to deliver innovative and affordable medicines globally.
